Document is current
Any future updates will be listed below
-
Authors
Bentvelzen, Mieke L. M. https://orcid.org/0009-0003-5054-1569
el Bouhaddani, Said https://orcid.org/0000-0002-2279-4337
Spierings, Julia https://orcid.org/0000-0002-2546-312X
Concepcion, Arno N.
Vonkeman, Harald E. https://orcid.org/0000-0003-3792-7718
Mooij, Shasti C. https://orcid.org/0009-0002-7517-7348
Schipper, Lydia G. https://orcid.org/0009-0007-6379-1240
Herman, Amin
Vreugdenhil, Simone A.
,
Bhansing, Kavish J.
van Bijnen, Sandra T. A.
Bisoendial, Radjesh J.
van Bon, Lenny
Jansen, Tim L. T. A.
van Kuijk, Arno W. R.
Kok, Marc R.
Leijten, Emmerik F. A.
Jahangier, Z. Nazira
van Tubergen, Astrid M.
Wijngaarden, Siska
Kadir, Sylvana W.
Comarniceanu, Antoaneta C.
Mastbergen, Simon C. https://orcid.org/0000-0002-8825-6486
Welsing, Paco M. J. https://orcid.org/0000-0003-2361-2803
-
Funding
Funding for this research was provided by:
Health Holland Top Sector Life Sciences & Health (LSHM17074)
- License Information
-
More Information
Article History
Received: 15 January 2026
Accepted: 4 March 2026
First Online: 12 March 2026
Declarations
:
: All patients provided written informed consent. The study was carried out in compliance with the Declaration of Helsinki and was approved by the Medical Research Ethics Committee in Utrecht, Netherlands (MREC reference number: NL63439.041.17).
: Not applicable.
: H.E.V. is paid consultant for (pharmaceutical) companies Abbvie, Novartis, Pfizer, UCB, Johnson and Johnson, Alphasigma, he received speaker fees from AstraZeneca, Lilly, Pfizer, and he received research grants from (pharmaceutical) companies: Galapagos and Boehringer Ingelheim. S.C.M. is supported by ReumaNederland LLP-9. J.S. received research grants from ReumaNederland, Vifor, Vasculitis Stichting, Zeldzame Ziektenfonds and Miltenyi Biotec, and she received speaker fees from Boehringer Ingelheim, Janssen and Novartis. The remaining authors declare that they have no competing interests.
